Gene therapy: Reality or myth for the global bleeding disorders community?

Haemophilia

Volumn 8, Issue 3, 2002, Pages 261-267

  Kelley, K ^a   Verma, I ^b   Pierce, G F ^c,d  

^a NEW ENGLAND BIOLABS   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c Selective Genetics Inc   (United States)

^d NONE   (United States)

Author keywords

Adeno associated virus; Adenovirus; Genetic disease; Haemophilia; Plasmids; Viral vectors

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE; PLASMID VECTOR; RETROVIRUS VECTOR; VACCINE; BLOOD CLOTTING FACTOR;

ADENO ASSOCIATED VIRUS; ARTICLE; BLEEDING DISORDER; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IN VIVO STUDY; PATIENT CARE; PRIORITY JOURNAL; TARGET ORGAN; VIRAL GENE DELIVERY SYSTEM; BLOOD CLOTTING DISORDER; ECONOMICS; HEALTH CARE DELIVERY; METHODOLOGY; REVIEW;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; GENE THERAPY; HEALTH SERVICES ACCESSIBILITY; HEMOPHILIA A; HUMANS;

EID: 0036588701     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00646.x     Document Type: Article

References (24)

1. Roth DA, Tawa NE Jr, O'Brien JM, Treco DA, Selden RF. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344: 1735-42.
2. Kay MA, Manno CS, Ragni MV et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-61.
3. Miller DG, Stamatoyannopoulos G. Gene therapy for hemophilia. N Engl J Med 2001; 344: 1782-4.
4. Chuah MK, Collen D, VandenDriessche T. Gene therapy for hemophilia. J Gene Med 2001; 3: 3-20.
5. High KA. Gene therapy: a 2001 perspective. Haemophilia 2001; 7 (Suppl. 1): 23-7.
6. Gura T. Hemophilia. After a setback, gene therapy progresses ⋯ gingerly. Science 2001; 291: 1692-7.
7. Thompson AR. Gene therapies for the hemophilias. Mol Ther 2000; 2: 5-8.
8. Snyder RO, Miao C, Meuse L et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5: 64-70.
9. Herzog RW, Yang EY, Couto LB et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
10. Balague C, Zhou J, Dai Y et al. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 2000; 95: 820-8.
11. Gallo-Penn AM, Shirley PS, Andrews JL et al. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood 2001; 97: 107-13.
12. Miao CH, Thompson AR, Loeb K, Ye X. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther 2001; 3: 947-57.
13. Ferber D. Gene therapy. Safer and virus-free? Science 2001; 294: 1638-42.
14. MASAC. MASAC Recommendations for Conducting Gene Therapy Clinical Trials in Persons with Bleeding Disorders, 2001. URL: http://www.hemophilia.org/programs/masac/masac/masac120.htm.
15. Kelley KC. Hemophilia treatment. An introduction to gene therapy. Haemophilia 2000; 6 (Suppl. 1): 110-4.
16. Faust SP. Desire and need: understanding hemophiliacs' participation in gene therapy trials. Mol Ther 2001; 4: 2-3.
17. Lusher JM. Gene therapy for hemophilia A and B. Patient selection and follow-up, requirements for a cure. Thromb Haemost 1999; 82: 572-5.
18. Pfeifer A, Verma IM. Gene therapy: promises and problems. Annu Rev Genomics Hum Genet 2001; 2: 177-211.
19. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9 [Erratum N Engl J Med 2001; 345: 384].
20. Ragni MV. New-generation recombinant factor concentrates: bridge to gene therapy. Haemophilia 2001; 7 (Suppl. 1): 28-35.
21. O'Mahoney B. Plasma-derived and Biotech Products: What is the Future of Haemophilia Therapy? World Federation of Hemophilia, 1999.
22. MASAC. MASAC Guidelines for the Management of Factor VIII Therapy. Prophylaxis, and Immune Tolerance Induction During the Current Shortage of Recombinant Factor VIII, 2001. URL: http://www.hemophilia.org/programs/masac/masac/masac114.htm
23. Proceedings of the Second WFH Global Forum on the Safety and Supply of Hemophilia Treatment Products, Montreal, February 2002.
24. Verma IM. Pharma + profits = continued AIDS epidemic. Mol Ther 2001; 3: 419.